Cannabis stocks slammed as earnings disappoint

Major medicinal cannabis producers in Canada saw their respective stocks begin to slide last week after the market leader reported a disappointing set of earnings results.

The medical cannabis industry took a hit last week after the largest company in the sector in terms of market cap, Canada-based Canopy Growth, saw its share price decline after reporting lower-than-expected revenues in its first quarter (Q1) of 2020.

‘While strong harvest figures should allay crop failure worries, elsewhere we see little to reassure investors that significant [sustainable] sales growth and profitability will be visible in the near future,’ Jefferies analyst Ryan Tomkins said in a note.

Canopy Growth’s share price fell as much as 15% to CAD 36.11 in the wake of its Q1 earnings on Thursday last week. The stock closed 4.27% lower at CAD 35.66 on Monday.

Canopy Growth earnings miss mark

Despite generating net revenue of $90.5 million in Q1, it was well below analysts’ forecasts, with the company also falling short in terms of bottom-line estimates too, with Canopy Growth blaming its lacklustre performance on high expansion costs.

‘The company remains focused on laying the foundation for dominance in an emerging global opportunity,’ Canopy Growth CEO Mark Zekulin said. ‘This means investments in developing intellectual property, building brands, building international reach, and ensuring scaled production capability for current and future products.’

‘Second, we are fixated on the process of evolving from builders to operators over the remainder of this fiscal year, meaning that as our expansion program comes to a close in Canada, and as new value-add products come to market in Canada, we demonstrate a sustainable, high margin, profitable Canadian business,’ he added.

Learn how to trade Canopy Growth and other cannabis stocks with IG

Cannabis rivals see similar stock declines

Canopy Growth’s disappointing performance has helped drag its peers’ stock lower too, with rivals Tilray, Chronos Group and Aurora Cannabis all down.

Since August 13, Tilray has seen its stock lose more than 30% of its value. Meanwhile, Chronos and Aurora have seen a 13% and 11% decline in their respective share price’s over the same period.


This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

See opportunity on a stock?

Don’t miss your chance. Try a risk-free trade in your demo account, and find out whether your hunch could have paid off.

  • Log in to your demo
  • Try a risk-free trade
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance. Upgrade to a live account to take advantage.

  • Trade a wide range of popular global stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform, when it matters

See opportunity on a stock?

Don’t miss your chance. Log in to take advantage while conditions prevail.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
Sell
Buy
-
-
-
-
-
-
-
-
-
-
Sell
Buy
Sell
Buy
-
-
China 300
-
-

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Sunday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.


For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.